Literature DB >> 21827914

Spinocerebellar ataxia type 14.

Dong-Hui Chen1, Wendy H Raskind, Thomas D Bird.   

Abstract

SCA14 is an autosomal dominant hereditary cerebellar ataxia that usually has an onset in early to mid adult life, with slow progression and normal lifespan. Although generally an uncomplicated cerebellar ataxia with gait imbalance, dysarthria, and nystagmus, there is occasionally sensory loss, hyperactive tendon reflexes, cognitive decline, or myoclonus. Brain MRI shows cerebellar atrophy. A single autopsy has shown loss of cerebellar Purkinje cells. The disease is caused by mutations in the protein kinase C gamma (PKCγ, PRKCG) gene with a hotspot for mutations in exon 4. Genetic testing for SCA14 is clinically available. 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21827914     DOI: 10.1016/B978-0-444-51892-7.00036-X

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  14 in total

Review 1.  Essential Tremor Within the Broader Context of Other Forms of Cerebellar Degeneration.

Authors:  Elan D Louis; Phyllis L Faust
Journal:  Cerebellum       Date:  2020-12       Impact factor: 3.847

2.  Carbonic Anhydrase 8 Expression in Purkinje Cells Is Controlled by PKCγ Activity and Regulates Purkinje Cell Dendritic Growth.

Authors:  Etsuko Shimobayashi; Wolfgang Wagner; Josef P Kapfhammer
Journal:  Mol Neurobiol       Date:  2015-09-23       Impact factor: 5.590

3.  Cerebellar pathology in childhood-onset vs. adult-onset essential tremor.

Authors:  Elan D Louis; Sheng-Han Kuo; William J Tate; Geoffrey C Kelly; Phyllis L Faust
Journal:  Neurosci Lett       Date:  2017-09-01       Impact factor: 3.046

Review 4.  The autosomal dominant spinocerebellar ataxias: emerging mechanistic themes suggest pervasive Purkinje cell vulnerability.

Authors:  Katherine E Hekman; Christopher M Gomez
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-08-18       Impact factor: 10.154

Review 5.  The Moonwalker mouse: new insights into TRPC3 function, cerebellar development, and ataxia.

Authors:  Esther B E Becker
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

6.  Deregulation of the actin cytoskeleton and macropinocytosis in response to phorbol ester by the mutant protein kinase C gamma that causes spinocerebellar ataxia type 14.

Authors:  Kazuhiro Yamamoto; Takahiro Seki; Hikaru Yamamoto; Naoko Adachi; Shigeru Tanaka; Izumi Hide; Naoaki Saito; Norio Sakai
Journal:  Front Physiol       Date:  2014-04-01       Impact factor: 4.566

7.  Cognition is only minimally impaired in Spinocerebellar ataxia type 14 (SCA14): a neuropsychological study of ten Norwegian subjects compared to intrafamilial controls and population norm.

Authors:  Iselin Marie Wedding; Jeanette Koht; Espen Dietrichs; Nils Inge Landrø; Chantal M E Tallaksen
Journal:  BMC Neurol       Date:  2013-11-29       Impact factor: 2.474

8.  Investigation of Visual System Involvement in Spinocerebellar Ataxia Type 14.

Authors:  Thomas Ihl; Ella M Kadas; Timm Oberwahrenbrock; Matthias Endres; Thomas Klockgether; Jan Schroeter; Alexander U Brandt; Friedemann Paul; Martina Minnerop; Sarah Doss; Tanja Schmitz-Hübsch; Hanna G Zimmermann
Journal:  Cerebellum       Date:  2020-08       Impact factor: 3.847

9.  Neurodegeneration in SCA14 is associated with increased PKCγ kinase activity, mislocalization and aggregation.

Authors:  Maggie M K Wong; Stephanie D Hoekstra; Jane Vowles; Lauren M Watson; Geraint Fuller; Andrea H Németh; Sally A Cowley; Olaf Ansorge; Kevin Talbot; Esther B E Becker
Journal:  Acta Neuropathol Commun       Date:  2018-09-24       Impact factor: 7.801

10.  Genotype-phenotype correlations, dystonia and disease progression in spinocerebellar ataxia type 14.

Authors:  Viorica Chelban; Sarah Wiethoff; Bjørn K Fabian-Jessing; Nourelhoda A Haridy; Alaa Khan; Stephanie Efthymiou; Esther B E Becker; Emer O'Connor; Joshua Hersheson; Katrina Newland; Allan Thomas Hojland; Pernille A Gregersen; Suzanne G Lindquist; Michael B Petersen; Jørgen E Nielsen; Michael Nielsen; Nicholas W Wood; Paola Giunti; Henry Houlden
Journal:  Mov Disord       Date:  2018-03-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.